SCOUTING
DashboardOpportunitiesPortfolioReports

SCOUTING Institutional Intelligence

Legal · Compliance · Security · © 2026 Scouting Inc.

Opportunities / VitaGenomics

VitaGenomics

Screened
Published
HealthUnited StatesSeries B
Spotted
Profiled
Screened
Pre-DD
Full DD

Executive Summary

Consumer genomics platform offering actionable health insights and pharmacogenomics

Source: a16z Bio portfolio referralSpotted: 5 Aug 2025

Company Profile

vitagenomics.comFounded: 10 Jan 2022Team: 65

VitaGenomics offers a DTC genomics platform with clinical-grade pharmacogenomic reports. Their proprietary ML pipeline analyzes whole-genome sequencing data to predict drug responses, disease predispositions, and optimal wellness plans. 280K kits sold with 94% customer satisfaction. B2B channel launched with 15 health systems.

Founders

Dr. Emily ZhangCEO
Dr. Michael TorresCSO
James ParkCTO

Investment Score

82
STRONG
Team & Governance (20%)
88
Market Opportunity (20%)
85
Product & Technology (15%)
90
Financial Performance (15%)
72
ESG & Impact (15%)
78
Strategic Fit (10%)
80
Timing & Deal Terms (5%)
76
Exceptional founding team with deep domain expertise — CEO is ex-Illumina VP, CSO published 40+ papers in Nature Genetics. Product-market fit is strong with organic growth accelerating. Main risk is regulatory uncertainty around DTC genomic health claims in the EU. Recommend advancing to Pre-DD.

Trust Indicators

Available at Pre-DD level

Team

DE
Dr. Emily ZhangCEO
DM
Dr. Michael TorresCSO
JP
James ParkCTO

Activity Log

Spotted on 5 Aug 2025
Profiled — Company data gathered
Screened — Investment score assigned
Pre-DD — Pending